On April 7 2021, the Food and Drug Administration
Post# of 148288
(Total Views: 506)
Posted On: 01/06/2022 1:28:34 PM
On April 7 2021, the Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy) for some patients with triple-negative breast cancer (TNBC).
Did Nader really not know they were going to be compared to this almost year old approval, or was it just another way to string us along for two months? Mention the BTD 8 billion plus value add all the while knowing it wouldn't go through without additional data. It's okay because they've got the NASH BTD to dangle for a couple months while they come up with the next carrot.
Watch this proactive video from 06/2019. For those of us that have been here the whole time, it's deja vu all over again.
Did Nader really not know they were going to be compared to this almost year old approval, or was it just another way to string us along for two months? Mention the BTD 8 billion plus value add all the while knowing it wouldn't go through without additional data. It's okay because they've got the NASH BTD to dangle for a couple months while they come up with the next carrot.
Watch this proactive video from 06/2019. For those of us that have been here the whole time, it's deja vu all over again.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼